La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Thermo Fisher Scientific Croissance future
Future contrôle des critères 1/6
Thermo Fisher Scientific devrait augmenter ses bénéfices et son chiffre d'affaires de 10.6% et de 5.6% par an respectivement. Le BPA devrait croître de de 11% par an. Le rendement des capitaux propres devrait être 17.5% dans 3 ans.
Informations clés
10.6%
Taux de croissance des bénéfices
10.9%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 17.9% |
| Taux de croissance des recettes | 5.6% |
| Rendement futur des capitaux propres | 17.7% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 26 Aug 2024 |
Mises à jour récentes de la croissance future
Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27
Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Recent updates
Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings
Aug 16Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Jul 25A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 11Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends
Jun 07Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Apr 30Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Apr 24Thermo Fisher Scientific: Too Hot To Handle
Apr 15Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)
Apr 02We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Mar 12Thermo Fisher's Bright Future Makes It A Great Buy On Weakness
Feb 06Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics
Jan 16Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'
Jan 06Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?
Dec 29Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Dec 11Thermo Fisher Scientific: I Am Still Waiting For An Attractive Buying Opportunity.
Dec 02Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07My Family Is Buying A Lot More Thermo Fisher Stock
Oct 31Thermo Fisher: An Up To 35% Undervalued Healthcare Gem I Like On Weakness
Sep 28Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 49,032 | 8,039 | 9,476 | 10,641 | 19 |
| 12/31/2025 | 45,711 | 6,925 | 8,643 | 9,495 | 24 |
| 12/31/2024 | 42,943 | 6,142 | 6,839 | 8,009 | 24 |
| 6/29/2024 | 42,346 | 6,220 | 7,963 | 9,348 | N/A |
| 3/30/2024 | 42,492 | 6,034 | 7,560 | 8,928 | N/A |
| 12/31/2023 | 42,857 | 5,995 | 6,927 | 8,406 | N/A |
| 9/30/2023 | 43,421 | 5,941 | 6,546 | 8,170 | N/A |
| 7/1/2023 | 43,524 | 5,721 | 5,854 | 7,693 | N/A |
| 4/1/2023 | 43,807 | 6,024 | 5,620 | 7,681 | N/A |
| 12/31/2022 | 44,915 | 6,950 | 6,911 | 9,154 | N/A |
| 10/1/2022 | 44,167 | 7,032 | 5,600 | 8,124 | N/A |
| 7/2/2022 | 42,820 | 7,439 | 6,336 | 8,837 | N/A |
| 4/2/2022 | 41,123 | 7,603 | 7,001 | 9,536 | N/A |
| 12/31/2021 | 39,211 | 7,725 | 6,789 | 9,312 | N/A |
| 10/2/2021 | 39,059 | 8,565 | 7,916 | 10,194 | N/A |
| 7/3/2021 | 38,250 | 8,596 | 8,132 | 10,252 | N/A |
| 4/3/2021 | 35,894 | 7,924 | 8,062 | 9,911 | N/A |
| 12/31/2020 | 32,218 | 6,375 | 6,815 | 8,289 | N/A |
| 9/26/2020 | 28,497 | 4,879 | 5,686 | 6,863 | N/A |
| 6/27/2020 | 26,248 | 3,706 | 4,245 | 5,272 | N/A |
| 3/28/2020 | 25,647 | 3,669 | 3,702 | 4,680 | N/A |
| 12/31/2019 | 25,542 | 3,696 | 4,047 | 4,973 | N/A |
| 9/28/2019 | 25,220 | 3,592 | 3,940 | 4,861 | N/A |
| 6/29/2019 | 24,868 | 3,541 | 4,086 | 4,964 | N/A |
| 3/30/2019 | 24,630 | 3,174 | 4,273 | 5,114 | N/A |
| 12/31/2018 | 24,358 | 2,938 | 3,785 | 4,543 | N/A |
| 9/29/2018 | 23,898 | 2,570 | 3,919 | 4,608 | N/A |
| 6/30/2018 | 23,094 | 2,395 | 3,689 | 4,317 | N/A |
| 3/31/2018 | 22,006 | 2,256 | N/A | 3,722 | N/A |
| 12/31/2017 | 20,918 | 2,228 | N/A | 4,005 | N/A |
| 9/30/2017 | 19,824 | 2,330 | N/A | 3,344 | N/A |
| 7/1/2017 | 19,199 | 2,270 | N/A | 3,220 | N/A |
| 4/1/2017 | 18,744 | 2,174 | N/A | 3,284 | N/A |
| 12/31/2016 | 18,274 | 2,025 | N/A | 3,258 | N/A |
| 10/1/2016 | 17,973 | 1,999 | N/A | 3,281 | N/A |
| 7/2/2016 | 17,606 | 2,003 | N/A | 3,220 | N/A |
| 4/2/2016 | 17,341 | 1,998 | N/A | 3,072 | N/A |
| 12/31/2015 | 16,965 | 1,980 | N/A | 2,942 | N/A |
| 9/26/2015 | 16,806 | 1,978 | N/A | 2,543 | N/A |
| 6/27/2015 | 16,854 | 1,971 | N/A | 2,475 | N/A |
| 3/28/2015 | 16,905 | 1,738 | N/A | 2,598 | N/A |
| 12/31/2014 | 16,890 | 1,896 | N/A | 2,620 | N/A |
| 9/27/2014 | 15,864 | 1,635 | N/A | 2,394 | N/A |
| 6/28/2014 | 14,884 | 1,482 | N/A | 2,224 | N/A |
| 3/29/2014 | 13,802 | 1,481 | N/A | 1,814 | N/A |
| 12/31/2013 | 13,090 | 1,279 | N/A | 2,011 | N/A |
| 9/28/2013 | 12,883 | 1,322 | N/A | 1,942 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de TMO ( 10.6% par an) est supérieure au taux d'épargne ( 2.5% ).
Bénéfices vs marché: Les bénéfices de TMO ( 10.6% par an) devraient croître plus lentement que le marché US ( 15.2% par an).
Croissance élevée des bénéfices: Les bénéfices de TMO devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de TMO ( 5.6% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de TMO ( 5.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de TMO devrait être faible dans 3 ans ( 17.5 %).